COMMUNIQUÉS West-GlobeNewswire

-
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
01/04/2024 -
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04/2024 -
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
01/04/2024 -
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
01/04/2024 -
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
01/04/2024 -
Smith+Nephew introduces the RENASYS™ EDGE Negative Pressure Wound Therapy System – an exciting new option in home-based care for patients living with chronic wounds
01/04/2024 -
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
01/04/2024 -
aTyr Pharma to Participate in April Investor Conferences
01/04/2024 -
Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
01/04/2024 -
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
01/04/2024 -
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
01/04/2024 -
Vor Bio to Participate in Upcoming Investor Conferences
01/04/2024 -
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
01/04/2024 -
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
01/04/2024 -
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
01/04/2024 -
Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus
01/04/2024 -
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
01/04/2024 -
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
01/04/2024 -
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
01/04/2024
Pages